Piramal Pharma has been in the spotlight recently due to its fluctuating share prices and notable financial updates. As of September 25, 2024, the share price of Piramal Pharma is ₹217.67, reflecting a decline of 1.75% from the previous day’s close of ₹231.44. This performance comes after a period of significant volatility in the stock market, particularly within the pharmaceutical sector.
Main Points
- 1 Current Piramal Pharma Shares and Market Overview
- 2 Piramal Pharma Shares Key Financial Metrics
- 3 Piramal Pharma Shares Recent Developments
- 4 Financial Performance Highlights
- 5 Piramal Pharma Shares Analyst Recommendations
- 6 Piramal Pharma Shares Technical Analysis
- 7 Piramal Pharma Shares Support and Resistance Levels
- 8 Piramal Pharma Shares Market Sentiment
- 9 Institutional Holdings
On this date, Piramal Pharma’s stock opened at ₹240 and reached a high of ₹244 during intraday trading, with a low of ₹236. The stock has shown a 52-week range between ₹88 and ₹244, indicating substantial growth over the past year. Despite this recent dip, the stock has appreciated by approximately 124.1% over the last year, showcasing its potential for long-term investors.
- Market Capitalization: ₹30,683.11 crore
- P/E Ratio: 1,123.78
- EPS (Earnings Per Share): ₹0.21
- Dividend Yield: 0%
- 52 Week High/Low: ₹243.99 / ₹87.50
The company reported a loss of ₹88.64 crore in its latest quarter (ending June 30, 2024), marking a shift from three consecutive profitable quarters. Despite this setback, Piramal Pharma’s annual revenue growth of 14.23% outperformed its three-year CAGR of 8.72%, highlighting resilience in its operational performance.
Financial Performance Highlights
Piramal Pharma’s recent quarterly results have drawn attention for several reasons:
- Revenue Growth: The company reported an increase in revenue from operations by 12% year-on-year, amounting to ₹1,951 crore in Q1 FY25.
- EBITDA Improvement: EBITDA grew by 31% year-on-year, reaching ₹221 crore with an EBITDA margin improvement of over 170 basis points compared to Q1 FY24.
- Successful FDA Inspections: The company successfully closed USFDA inspections at its Lexington facility with zero observations, reinforcing its commitment to quality and compliance.
Analysts have mixed sentiments regarding Piramal Pharma’s stock:
- Strong Buy Recommendations: Several analysts maintain a “Strong Buy” rating based on the company’s robust operational metrics and market position.
- Target Prices: Some investment firms have set target prices ranging from ₹115 to ₹180, indicating potential upside despite recent losses.
From a technical perspective, Piramal Pharma’s stock is positioned above key moving averages:
- 50-Day Moving Average: Approximately ₹238.77
- 200-Day Moving Average: Approximately ₹150.91
The stock’s current price is comfortably above these averages, suggesting bullish momentum in the short to medium term.
Investors should be aware of critical support and resistance levels:
| Support Level | Resistance Level |
|---|---|
| ₹218.70 | ₹241.99 |
| ₹205.96 | ₹252.54 |
| ₹195.41 | ₹265.28 |
These levels are crucial for traders looking to enter or exit positions effectively.
The overall market sentiment towards Piramal Pharma remains cautiously optimistic despite recent challenges:
- The decline in share price might present a buying opportunity for investors looking for long-term growth.
- Increased demand for pharmaceutical products and services continues to drive interest in the sector.
Institutional Holdings
Recent reports indicate a decline in institutional holdings in Piramal Pharma, which could be seen as a negative indicator by some investors. However, this trend may also reflect broader market dynamics rather than company-specific issues.
Disclaimer: The information given in this article is from investment experts and brokerage companies, they do not represent Local Haryana. Before taking any investment related decision, you must consult a certified expert.
